Medical Coverage Policy Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
|
|
- Jack Neal
- 5 years ago
- Views:
Transcription
1 Medical Coverage Policy Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence EFFECTIVE DATE: POLICY LAST UPDATED: OVERVIEW Bulking agents are injectable substances used to increase tissue bulk. They can be injected periurethrally to treat urinary incontinence and perianally to treat fecal incontinence. The U.S. Food and Drug Administration (FDA) has approved several bulking agent products for treating urinary incontinence and 1 for treating fecal incontinence. This policy is applicable to Commercial Products only. For Blue CHiP for Medicare, see related policy section. MEDICAL CRITERIA Not applicable. PRIOR AUTHORIZATION Not applicable. POLICY STATEMENT Commercial Products Urinary Incontinence The use of carbon-coated spheres, calcium hydroxylapatite, or polydimethylsiloxane may be considered medically necessary to treat stress urinary incontinence in men and women who have failed appropriate conservative therapy. The use of autologous cellular therapy (eg, myoblasts, fibroblasts, muscle-derived stem cells, adipose-derived stem cells), autologous fat, autologous ear chondrocytes, or any other periurethral bulking agent not listed above, including, but not limited to Teflon to treat stress urinary incontinence is considered not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes. The use of periurethral bulking agents to treat urge urinary incontinence is considered not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes. Fecal Incontinence The use of perianal bulking agents to treat fecal incontinence is considered is considered not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes. COVERAGE Benefits may vary between groups/contracts. Please refer to the appropriate Subscriber Agreement for limitations of benefits/coverage when services are not medically necessary. BACKGROUND Injectable bulking agents are space-filling substances used to increase tissue bulk. When used to treat stress urinary incontinence (SUI), bulking agents are injected periurethrally to increase tissue bulk and thereby increase resistance to the outflow of urine. The bulking agent is injected into the periurethral tissue as a liquid that solidifies into a spongy material to bulk the urethral wall. Bulking agents may be injected over a course of 500 EXCHANGE STREET, PROVIDENCE, RI MEDICAL COVERAGE POLICY 1
2 several treatments until the desired effect is achieved. Periurethral bulking agents have been widely used for incontinence in women. Men have also been treated, typically those with postprostatectomy incontinence. After the success of periurethral bulking agents for treating SUI, bulking agents injected into the anal canal have been proposed to treat fecal incontinence. In particular, bulking agents are a potential treatment for passive fecal incontinence associated with internal anal sphincter dysfunction. The bulking agent is injected into the submucosa of the anal canal to increase tissue bulk in the area, which narrows the opening of the anus. Current treatment options for fecal incontinence include conservative measures (eg, dietary changes, pharmacotherapy, pelvic floor muscle exercises), sacral nerve stimulation, and surgical interventions to correct an underlying problem. Key factors in determining the optimal product are biocompatibility, durability, and absence of migration. A number of periurethral bulking agents to treat urinary incontinence have been cleared for marketing by the Food and Drug Administration (FDA); however, products developed to date have not necessarily met all criteria of the ideal bulking agents. The first FDA-approved product was cross-linked collagen (eg, Contigen). The agent was found to be absorbed over time and symptoms could recur, requiring additional injections. Contigen production was discontinued in Other periurethral bulking agents cleared by FDA for urinary incontinence include carbon-coated beads (eg, Durasphere), spherical particles of calcium hydroxylapatite (CaHA) in a gel carrier (Coaptite), polydimethylsiloxane (silicone, Macroplastique), and ethylene vinyl alcohol copolymer implants (eg, Tegress, formerly Uryx). Tegress was voluntarily removed from the market due to safety concerns. Several agents identical to or similar to those used for urinary incontinence (eg, Durasphere, silicone biomaterial) have been studied for the treatment of fecal incontinence. To date, only 1 bulking agent has been approved by FDA for fecal incontinence. This formulation is a non-animal-stabilized hyaluronic acid/dextranomer in stabilized hyaluronic acid (NASHA Dx) and is marketed by Q-Med as Solesta. A hyaluronic acid/dextranomer formulation (Deflux ) from the same company has been commercially available for a number of years for the treatment of vesicoureteral reflux in children (see evidence review on the treatment of vesicoureteral reflux with bulking agents). Autologous fat and autologous ear chondrocytes have also been used as periurethral bulking agents; autologous substances do not require FDA approval. Polytetrafluoroethylene (Teflon) has been investigated as an implant material but does not have FDA approval. A more recently explored alternative is cellular therapy with myoblasts, fibroblasts, or stem cells (muscle-derived or adipose-derived). In addition to their use as periurethral bulking agents, it is hypothesized that transplanted stem cells would undergo self-renewal and multipotent differentiation, which could result in regeneration of the sphincter and its neural connections. For individuals who have fecal incontinence who receive injectable bulking agents, the evidence includes RCTs and systematic reviews of RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, and treatment-related morbidity. A comparative effectiveness review from the Agency for Healthcare Research and Quality evaluated 2 RCTs with the FDA-approved product NASHA Dx (Solesta) and 2 RCTs with Durasphere (off-label in the United States). One RCT comparing NASHA Dx with sham found that NASHA Dx improved some outcome measures but not others. The other RCT did not find a significant difference in efficacy between NASHA Dx and biofeedback. Two additional RCTs evaluating Durasphere found only short-term improvements in fecal incontinence severity. Controlled trials with longer follow-up are important to determine the durability of any treatment effect. The evidence is insufficient to determine the effects of the technology on health outcomes. CODING Commercial Products The following codes are not medically necessary: 0377T Anoscopy with directed submucosal injection of bulking agent for fecal incontinence L8605 Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, anal canal, 1 ml, includes shipping and necessary supplies 500 EXCHANGE STREET, PROVIDENCE, RI MEDICAL COVERAGE POLICY 2
3 The following codes are medically necessary when filed with N39.3 -Stress incontinence (female) (male) L8603 Injectable bulking agent, collagen implant, urinary tract, 2.5 ml syringe, includes shipping and necessar L8606 Injectable bulking agent synthetic implant, urinary tract, 1 ml syringe, includes shipping and necessary supplies There no specific HCPCS for bulking agents that are not medically necessary. Claims should be filed with an unlisted HCPCS code RELATED POLICIES BlueCHiP for Medicare National and Local Coverage Determinations Policy PUBLISHED Provider Update February 2019 Provider Update October 2017 Provider Update January 2017 Provider Update Dec 2015 Provider Update July 2014 Policy Update April 2013 REFERENCES: 1. Kirchin V, Page T, Keegan PE, et al. Urethral injection therapy for urinary incontinence in women. Cochrane Database Syst Rev. 2012;2:CD PMID Davila GW. Nonsurgical outpatient therapies for the management of female stress urinary incontinence: long-term effectiveness and durability. Adv Urol. 2011;2011: PMID Agency for Health Care Policy and Research. Clinical Practice Guideline. Urinary Incontinence in Adults. Rockville, MD: Department of Health and Human Services Corcos J, Collet JP, Shapiro S, et al. Multicenter randomized clinical trial comparing surgery and collagen injections for treatment of female stress urinary incontinence. Urology. May 2005;65(5): PMID Lightner D, Calvosa C, Andersen R, et al. A new injectable bulking agent for treatment of stress urinary incontinence: results of a multicenter, randomized, controlled, double-blind study of Durasphere. Urology. Jul 2001;58(1): PMID U.S. Food and Drug Administration. FDA Summary of Safety and Effectiveness: URYX Urethral Bulking Agent. 2004, December 16; Accessed August 10, Hurtado E, McCrery R, Appell R. The safety and efficacy of ethylene vinyl alcohol copolymer as an intraurethral bulking agent in women with intrinsic urethral deficiency. Int Urogynecol J Pelvic Floor Dysfunct. Aug 2007;18(8): PMID Mayer RD, Dmochowski RR, Appell RA, et al. Multicenter prospective randomized 52-week trial of calcium hydroxylapatite versus bovine dermal collagen for treatment of stress urinary incontinence. Urology. May 2007;69(5): PMID Ghoniem G, Corcos J, Comiter C, et al. Cross-linked polydimethylsiloxane injection for female stress urinary incontinence: results of a multicenter, randomized, controlled, single-blind study. J Urol. Jan 2009;181(1): PMID Ghoniem G, Corcos J, Comiter C, et al. Durability of urethral bulking agent injection for female stress urinary incontinence: 2-year multicenter study results. J Urol. Apr 2010;183(4): PMID Lightner D, Rovner E, Corcos J, et al. Randomized controlled multisite trial of injected bulking agents for women with intrinsic sphincter deficiency: mid-urethral injection of Zuidex via the Implacer versus proximal urethral injection of Contigen cystoscopically. Urology. Oct 2009;74(4): PMID Chapple CR, Haab F, Cervigni M, et al. An open, multicentre study of NASHA/Dx Gel (Zuidex) for the treatment of stress urinary incontinence. Eur Urol. Sep 2005;48(3): PMID EXCHANGE STREET, PROVIDENCE, RI MEDICAL COVERAGE POLICY 3
4 13. Lone F, Sultan AH, Thakar R. Long-term outcome of transurethral injection of hyaluronic acid/dextranomer (NASHA/Dx gel) for the treatment of stress urinary incontinence (SUI). Int Urogynecol J. Nov 2010;21(11): PMID Sokol ER, Karram MM, Dmochowski R. Efficacy and safety of polyacrylamide hydrogel for the treatment of female stress incontinence: a randomized, prospective, multicenter North American study. J Urol. Sep 2014;192(3): PMID Pai A, Al-Singary W. Durability, safety and efficacy of polyacrylamide hydrogel (Bulkamid((R))) in the management of stress and mixed urinary incontinence: three year follow up outcomes. Cent European J Urol. 2015;68(4): PMID Lose G, Sorensen HC, Axelsen SM, et al. An open multicenter study of polyacrylamide hydrogel (Bulkamid(R)) for female stress and mixed urinary incontinence. Int Urogynecol J. Dec 2010;21(12): PMID Leone Roberti Maggiore U, Alessandri F, Medica M, et al. Outpatient periurethral injections of polyacrylamide hydrogel for the treatment of female stress urinary incontinence: effectiveness and safety. Arch Gynecol Obstet. Jul 2013;288(1): PMID Mouritsen L, Lose G, Moller-Bek K. Long-term follow-up after urethral injection with polyacrylamide hydrogel for female stress incontinence. Acta Obstet Gynecol Scand. Feb 2014;93(2): PMID Lee PE, Kung RC, Drutz HP. Periurethral autologous fat injection as treatment for female stress urinary incontinence: a randomized double-blind controlled trial. J Urol. Jan 2001;165(1): PMID Bent AE, Tutrone RT, McLennan MT, et al. Treatment of intrinsic sphincter deficiency using autologous ear chondrocytes as a bulking agent. Neurourol Urodyn. 2001;20(2): PMID Strasser H, Marksteiner R, Margreiter E, et al. Autologous myoblasts and fibroblasts versus collagen for treatment of stress urinary incontinence in women: a randomised controlled trial. Lancet. Jun ;369(9580): PMID Kleinert S, Horton R. Retraction--autologous myoblasts and fibroblasts versus collagen [corrected] for treatment of stress urinary incontinence in women: a [corrected] randomised controlled trial. Lancet. Sep ;372(9641): PMID Peters KM, Dmochowski RR, Carr LK, et al. Autologous muscle derived cells for treatment of stress urinary incontinence in women. J Urol. Aug 2014;192(2): PMID Forte ML, Andrade KE, Butler M, et al. Treatments for Fecal Incontinence. Comparative Effectiveness Review No. 165 (Prepared by the Minnesota Evidence-based Practice Center under Contract No I.) AHRQ Publication No. 15(16)-EHC037-EF. Rockville, MD; Agency for Healthcare Research and Quality: March Accessed August 10, Maeda Y, Laurberg S, Norton C. Perianal injectable bulking agents as treatment for faecal incontinence in adults. Cochrane Database Syst Rev. 2013;2:CD PMID Hussain ZI, Lim M, Stojkovic SG. Systematic review of perianal implants in the treatment of faecal incontinence. Br J Surg. Nov 2011;98(11): PMID Leung FW. Treatment of fecal incontinence - review of observational studies (OS) and randomized controlled trials (RCT) related to injection of bulking agent into peri-anal tissue. J Interv Gastroenterol. Oct 2011;1(4): PMID Graf W, Mellgren A, Matzel KE, et al. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial. Lancet. Mar ;377(9770): PMID Dehli T, Stordahl A, Vatten LJ, et al. Sphincter training or anal injections of dextranomer for treatment of anal incontinence: a randomized trial. Scand J Gastroenterol. Mar 2013;48(3): PMID EXCHANGE STREET, PROVIDENCE, RI MEDICAL COVERAGE POLICY 4
5 i ii CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association. 500 EXCHANGE STREET, PROVIDENCE, RI MEDICAL COVERAGE POLICY 5
Protocol. Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Injectable Bulking Agents for the Treatment of Urinary and Fecal (70119) Medical Benefit Effective Date: 07/01/15 Next Review Date: 05/18 Preauthorization No Review Dates: 01/08, 11/08, 09/09, 09/10, 09/11,
More informationPeriurethral Bulking Agents for the Treatment of Urinary Incontinence. Original Policy Date
MP 7.01.14 Periurethral Bulking Agents for the Treatment of Urinary Incontinence Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature
More informationInjectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Policy Number: 7.01.19 Last Review: 6/2014 Origination: 2/1994 Next Review: 6/2015 Policy Blue Cross and Blue Shield of Kansas
More informationName of Policy: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Name of Policy: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Policy #: 455 Latest Review Date: July 2014 Category: Surgery Policy Grade: B Background/Definitions: As a
More informationInjectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Policy Number: 7.01.19 Last Review: 6/2017 Origination: 2/1994 Next Review: 6/2018 Policy Blue Cross and Blue Shield of Kansas
More informationMedical Policy Title: Periurethral Bulking ARBenefits Approval: <Date>
Medical Policy Title: Periurethral Bulking ARBenefits Approval: Agents for the Treatment of Incontinence Effective Date: 01/01/2012 Document: ARB0279 Revision Date: Code(s): 51715 Endoscopic injection
More informationInjectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Last Review Status/Date: March 2017 Page: 1 of 16 Urinary and Fecal Incontinence Description Bulking agents are injectable substances used to increase tissue bulk. They can be injected periurethrally to
More informationInjectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Last Review Status/Date: September 2015 Page: 1 of 16 Urinary and Fecal Incontinence Description Bulking agents are injectable substances that used to increase tissue bulk. They can be injected periurethrally
More informationMP Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Medical Policy MP 7.01.19 BCBSA Ref. Policy: 7.01.19 Last Review: 08/30/2017 Effective Date: 08/30/2017 Section: Surgery End Date: 08/19/2018 Related Policies 1.01.17 Pelvic Floor Stimulation as a Treatment
More informationMP Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
Medical Policy MP 7.01.19 BCBSA Ref. Policy: 7.01.19 Last Review: 08/20/2018 Effective Date: 08/20/2018 Section: Surgery Related Policies 1.01.17 Pelvic Floor Stimulation as a Treatment of Urinary and
More informationCorporate Medical Policy
Corporate Medical Policy Injectable Bulking Agents for the Treatment of Urinary and Fecal File Name: Origination: Last CAP Review: Next CAP Review: Last Review: injectable_bulking_agents_for_the_treatment_of_urinary_and_fecal_incontinence
More informationInjectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
7.01.19 Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence Section 7.0 Surgery Subsection Effective Date February 27, 2015 Original Policy Date February 27, 2015 Next Review
More informationMEDICAL POLICY SUBJECT: BULKING AGENTS FOR TREATMENT OF URINARY OR FECAL INCONTINENCE. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: BULKING AGENTS FOR (ARCHIVED DATE: 05/28/09-, EDITED DATE: 05/27/10, 05/19/11, 05/24/12, 05/23/13) PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Injectable Bulking Agents for the Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See Also: Injectable Bulking Agents for the Treatment of Urinary and
More informationInjectable Bulking Agents for the Treatment of Fecal Incontinence. Policy Specific Section: September 27, 2013 January 1, 2015
Medical Policy Injectable Bulking Agents for the Treatment of Fecal Incontinence Type: Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective Date: September 27,
More informationSubject: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence
09-A9000-03 Original Effective Date: 02/15/12 Reviewed: 12/06/18 Revised: 12/15/18 Subject: Injectable Bulking Agents for the Treatment of Urinary and Fecal Incontinence THIS MEDICAL COVERAGE GUIDELINE
More informationINJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE
FECAL INCONTINENCE Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationFecal Incontinence. Sphincter Augmentation. Alaiyan Bilal MD Hadassah mt scopus
Fecal Incontinence Sphincter Augmentation Alaiyan Bilal MD Hadassah mt scopus AUGMENTATION METHODS Injectables( Bulking agents) Radiofrequency INJECTABLES Biomaterials Polytef, Autologous fat, GAX (glutaraldehyde
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Injectable Bulking Agents for Urinary Conditions and Fecal Incontinence Table of Contents Coverage Policy... 1 General Background... 2 Coding/Billing Information...
More informationClinical Policy: Urinary Incontinence Devices and Treatments
Clinical Policy: Reference Number: CP.MP.142 Last Review Date: 03/18 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications Revision Log Description
More informationUrinary Incontinence. Biopolymer GmbH & Co.KG - Germany
Urinary Incontinence Treatment Options: 1. Physical Therapy: a conservative early stage treatment for UI, including pelvic floor muscles training known as Kegel exercise. 2. Medications: by means of pharmaceutical
More informationCorporate Medical Policy
Corporate Medical Policy Vesicoureteral Reflux, Treatment with Periureteral Bulking Agents File Name: Origination: Last CAP Review: Next CAP Review: Last Review: vesicoureteral_reflux_treatment_with_periureteral_bulking_agents
More informationClinical Policy Title: Injectable bulking agents fecal incontinence
Clinical Policy Title: Injectable bulking agents fecal incontinence Clinical policy number: 08.02.04 Effective Date: October 1, 2015 Initial Review Date: May 20, 2015 Most Recent Review Date: June 5, 2018
More informationClinical Policy Title: Injectable bulking agents for fecal incontinence
Clinical Policy Title: Injectable bulking agents for fecal incontinence Clinical policy number: 08.02.04 Effective Date: October 1, 2015 Initial Review Date: May 20, 2015 Most Recent Review Date: June
More informationBlueCHiP for Medicare Not applicable
Medical Coverage Policy Hearing Aid Mandate EFFECTIVE DATE: 01 14 2014 POLICY LAST UPDATED: 09 04 2018 OVERVIEW As defined by the Mandate, "hearing aid is any nonexperimental, wearable instrument or device
More informationPROLIA: Medical Coverage Policy Denosumab (Prolia and. Xgeva) EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Denosumab (Prolia and Xgeva) EFFECTIVE DATE: 11 01 2016 POLICY LAST UPDATED: 12 19 2017 OVERVIEW Prolia (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis
More information6 Page Male Incontinence Booklet 10/09/ :44 Page 1. The Natural Non-Surgical Option for Male Urinary Incontinence
6 Page Male Incontinence Booklet /9/ :44 Page The Natural Non-Surgical Option for Male Urinary Incontinence 6 Page Male Incontinence Booklet /9/ :44 Page Stress Urinary Incontinence - A Stressful Prospect
More informationTitle: Zuidex versus Contigen for Stress Urinary Incontinence. Date: May 30, 2007
Title: Zuidex versus Contigen for Stress Urinary Incontinence Date: May 30, 2007 Context and policy issues: Stress urinary incontinence (SUI) is the involuntary leakage of urine during exercise or movements
More informationA Case of Fecal Incontinence: Medical and Interventional Treatment Options
A Case of Fecal Incontinence: Medical and Interventional Treatment Options HPI JP is a 69 year-old F with a 12-month history of FI. Her symptoms began after a colonoscopy She has been experiencing passive
More informationClinical Policy: Fecal Incontinence Treatments Reference Number: PA.CP.MP.137
Clinical Policy: Fecal Incontinence Treatments Reference Number: PA.CP.MP.137 Effective Date: 01/18 Last Review Date: 12/16 Coding Implications Revision Log Description Fecal incontinence defined as the
More informationMedical Coverage Policy Prostatic Urethral Lifts
Medical Coverage Policy Prostatic Urethral Lifts EFFECTIVE DATE:01 01 2017 POLICY LAST UPDATED: 10 03 2017 OVERVIEW Benign prostatic hyperplasia is a common condition in older men that can lead to increased
More informationONE of the following:
Medical Coverage Policy Belimumab (Benlysta) EFFECTIVE DATE: 01 01 2012 POLICY LAST UPDATED: 11 21 2017 OVERVIEW Belimumab (Benlysta ) is indicated for the treatment of adult patients with active, autoantibody-positive,
More informationPayment Policy Drug Testing EFFECTIVE DATE: POLICY LAST UPDATED:
Payment Policy Drug Testing EFFECTIVE DATE: 05 23 2013 POLICY LAST UPDATED: 06 05 2018 OVERVIEW This policy documents the criteria and documentation requirements for immunoassay (IA) testing (also called
More informationMedical Policy. Description/Scope. Position Statement
Subject: Document #: Current Effective Date: 03/29/2017 Status: Revised Last Review Date: 02/02/2017 Description/Scope This document addresses the following treatments for urinary incontinence: Vaginal
More informationMedical Policy Title: Radiofrequency ARBenefits Approval: 10/19/2011
Medical Policy Title: Radiofrequency ARBenefits Approval: 10/19/2011 Treatment, Urinary Stress Incontinence, Transurethral Effective Date: 01/01/2012 Document: ARB0359 Revision Date: Code(s): 53860 Transurethral
More informationOsteochondral allografting for all other joints is not covered as the evidence is insufficient to determine the
Medical Coverage Policy Osteochondral Autologous Chrondrocyte Implantation for Focal Articular Cartilage Lesions EFFECTIVE DATE: 05 20 2008 POLICY LAST UPDATED: 10 16 2018 OVERVIEW A variety of procedures
More informationd EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Epidural Injections for Pain Management d EFFECTIVE DATE: 04 01 2018 POLICY LAST UPDATED: 03 20 2018 OVERVIEW Epidural injections are generally performed to treat pain arising from
More informationProtocol. Periureteral Bulking Agents as a Treatment of Vesicoureteral Reflux
Protocol Periureteral Bulking Agents as a Treatment of Vesicoureteral Reflux (701102) Medical Benefit Effective Date: 10/01/14 Next Review Date: 11/19 Preauthorization No Review Dates: 09/10, 09/11, 09/12,
More informationPopulations Interventions Comparators Outcomes Individuals: With urinary incontinence (women)
Protocol Biofeedback as a Treatment of Urinary Incontinence in Adults (20127) Medical Benefit Effective Date: 01/01/10 Next Review Date: 09/18 Preauthorization No Review Dates: 01/08, 11/08, 09/09, 09/10,
More informationMedical Coverage Policy Monitored Anesthesia care (MAC) EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Monitored Anesthesia care (MAC) EFFECTIVE DATE: 09 01 2004 POLICY LAST UPDATED: 01 08 2013 OVERVIEW Monitored anesthesia care is a specific anesthesia service for a diagnostic or
More informationComparison of Autologous, Non-autologous, and Synthetic Periurethral Bulking Agents
Comparison of Autologous, Non-autologous, and Synthetic Periurethral Bulking Agents Abstract Andrew J. Steward Department of Aerospace and Mechanical Engineering University of Notre Dame, Notre Dame, IN
More informationMEDICAL POLICY SUBJECT: PERCUTANEOUS POSTERIOR TIBIAL NERVE STIMULATION (PPTNS)
MEDICAL POLICY 03/19/15, 05/17/16 PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria
More informationClinical Policy: Fecal Incontinence Treatments Reference Number: CP.MP.137 Last Review Date: 12/17
Clinical Policy: Reference Number: CP.MP.137 Last Review Date: 12/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Fecal
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: July 15, 2018 Related Policies: 1.01.17 Pelvic Floor Stimulation as a Treatment of Urinary and Fecal Incontinence 2.01.58 Transanal Radiofrequency Treatment of
More informationMEDICAL POLICY SUBJECT: PERCUTANEOUS POSTERIOR TIBIAL NERVE STIMULATION (PPTNS) POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: PERCUTANEOUS POSTERIOR Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally
More informationProtocol. Periureteral Bulking Agents as a Treatment of Vesicoureteral Reflux
Protocol Periureteral Bulking Agents as a Treatment of Vesicoureteral Reflux (701102) Medical Benefit Effective Date: 10/01/14 Next Review Date: 11/18 Preauthorization Yes Review Dates: 09/10, 09/11, 09/12,
More informationW17: Intrinsic Sphincteric Deficiency, Diagnosis and Management Workshop Chair: Sherif Mourad, Egypt 20 October :00-18:00
W7: Intrinsic Sphincteric Deficiency, Diagnosis and Management Workshop Chair: Sherif Mourad, Egypt 20 October 204 4:00-8:00 Start End Topic Speakers 4:00 4:05 Introduction Sherif Mourad 4:05 4:20 Pathophysiology
More informationTransvaginal and Transurethral Radiofrequency Tissue Remodeling for Urinary Stress Incontinence
Transvaginal and Transurethral Radiofrequency Tissue Remodeling for Urinary Stress Incontinence Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary,
More informationNutrition Therapy. Medical Coverage Policy Enteral/Parenteral EFFECTIVE DATE: POLICY LAST UPDATED: 11/20/2018 OVERVIEW
Medical Coverage Policy Enteral/Parenteral Nutrition Therapy EFFECTIVE DATE: 01 20 2007 POLICY LAST UPDATED: 11/20/2018 OVERVIEW This policy describes the reimbursement for enteral and parenteral nutrition
More informationDuc M. Vo, MD, FACS Northwest Surgical Specialists
Duc M. Vo, MD, FACS Northwest Surgical Specialists Disclosures none Outline Definition Etiologies Exam findings Additional testing Medical management Surgical options What is fecal incontinence? Recurrent
More informationsad EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Outpatient Pulmonary Rehabilitation sad EFFECTIVE DATE: 07 07 2009 POLICY LAST UPDATED: 10 02 2018 OVERVIEW Pulmonary rehabilitation (PR) is a multidisciplinary approach to reducing
More informationPeriureteral Bulking Agents as a Treatment of Vesicoureteral Reflux (VUR)
Periureteral Bulking Agents as a Treatment of Vesicoureteral Reflux (VUR) Policy Number: 7.01.102 Last Review: 5/2018 Origination: 5/2006 Next Review: 5/2019 Policy Blue Cross and Blue Shield of Kansas
More informationMedical Coverage Policy Progenitor Cell Therapy for the Treatment of Damaged Myocardium due to Ischemia
Medical Coverage Policy Progenitor Cell Therapy for the Treatment of Damaged Myocardium due to Ischemia EFFECTIVE DATE: 02 01 2017 POLICY LAST UPDATED: 02 20 2018 OVERVIEW Progenitor cell therapy describes
More informationA minimally invasive treatment for stress urinary incontinence
A minimally invasive treatment for stress urinary incontinence This booklet provides information about the Bulkamid hydrogel for the treatment of stress urinary incontinence What is stress urinary incontinence?
More informationSubject: Percutaneous Tibial Nerve Stimulation
02-64000-01 Original Effective Date: 05/15/08 Reviewed: 05/24/18 Revised: 06/15/18 Subject: Percutaneous Tibial Nerve Stimulation THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION,
More informationThis policy is applicable to Commercial Products only. For BlueCHiP for Medicare, see Related Policy section.
Medical Coverage Policy Multimarker Serum Testing Related to Ovarian Cancer EFFECTIVE DATE: 10 01 2015 POLICY LAST UPDATED: 04 17 2018 OVERVIEW This policy documents the coverage determination for Multimarker
More informationMedical Coverage Policy Circulating Tumor DNA and. Circulating Tumor Cells for Cancer Management (Liquid Biopsy)
Medical Coverage Policy Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy) EFFECTIVE DATE: 12 01 2016 POLICY LAST UPDATED: 07 17 2018 OVERVIEW Circulating tumor DNA
More informationMEDICAL POLICY SUBJECT: BIOFEEDBACK
MEDICAL POLICY PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationOperative Approach to Stress Incontinence. Goals of presentation. Preoperative evaluation: Urodynamic Testing? Michelle Y. Morrill, M.D.
Operative Approach to Stress Incontinence Goals of presentation Michelle Y. Morrill, M.D. Director of Urogynecology The Permanente Medical Group Kaiser, San Francisco Review preoperative care & evaluation
More informationGamal Ghoniem,*, Jacques Corcos, Craig Comiter, Peter Bernhard, O. Lenaine Westney and Sender Herschorn
Cross-Linked Polydimethylsiloxane Injection for Female Stress Urinary Incontinence: Results of a Multicenter, Randomized, Controlled, Single-Blind Study Gamal Ghoniem,*, Jacques Corcos, Craig Comiter,
More informationFor Commercial products, please refer to the following policy: Preauthorization via Web-Based Tool for Procedures
Medical Coverage Policy Total Joint Arthroplasty Hip and Knee EFFECTIVE DATE: 08/01/2017 POLICY LAST UPDATED: 06/06/2017 OVERVIEW Joint replacement surgery, also known as arthroplasty, has proved to be
More informationAn Open, Multicentre Study of NASHA/Dx Gel (Zuidex TM ) for thetreatment of Stress Urinary Incontinence
European Urology European Urology 48 (2005) 488 494 Female UrologyöIncontinence An Open, Multicentre Study of NASHA/Dx Gel (Zuidex TM ) for thetreatment of Stress Urinary Incontinence Christopher R. Chapple
More information2/5/2016. ABS Complications. Anal Slings-investigational
ABS Complications Anal Slings-investigational Similar to transvaginal tape or transobturator tape for UI Dacron, mersilene, polyester, and teflon mesh, fascia lata Wound infections, sinus tract, t ulcer
More informationMedical Coverage Policy Percutaneous Vertebroplasty and Scaroplasty
Medical Coverage Policy Percutaneous Vertebroplasty and Scaroplasty EFFECTIVE DATE: 02 01 2011 POLICY LAST UPDATED: 07 02 2013 OVERVIEW Percutaneous vertebroplasty is an interventional technique involving
More informationsad EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Aqueous Shunts and Stents for Glaucoma sad EFFECTIVE DATE: 08 19 2014 POLICY LAST UPDATED: 09 18 2018 OVERVIEW Glaucoma surgery is intended to reduce intraocular pressure (IOP)
More informationMEDICAL POLICY SUBJECT: SACRAL NERVE STIMULATION
MEDICAL POLICY 01/16/14, 01/22/15, 03/15/16 PAGE: 1 OF: 8 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy
More informationCorporate Medical Policy
Corporate Medical Policy Percutaneous Tibial Nerve Stimulation for Voiding Dysfunction File Name: Origination: Last CAP Review: Next CAP Review: Last Review: percutaneous_tibial_nerve_stimulation_for_voiding_dysfunction
More informationThis policy is applicable to Commercial Products only. For BlueCHiP for Medicare, see related policy section.
Medical Coverage Policy Ophthalmologic Techniques that Evaluate the Posterior Segment for Glaucoma EFFECTIVE DATE: 01 01 2017 POLICY LAST UPDATED: 09 18 2018 OVERVIEW Several techniques have been developed
More informationReceived May 25, 2008; Revised January 21, 2009; Accepted May 17, 2009; Published June 12, 2009
Review Special Issue: Update on Lower Urinary Tract Symptoms TheScientificWorldJOURNAL (2009) 9, 466 478 TSW Urology ISSN 1537-744X; DOI 10.1100/tsw.2009.53 Minimally Invasive Therapies for Female Stress
More informationPeriureteral Bulking Agents as a Treatment of Vesicoureteral Reflux. Original Policy Date
MP 7.01.82 Periureteral Bulking Agents as a Treatment of Vesicoureteral Reflux Medical Policy Section Surgery Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature
More informationPercutaneous Tibial Nerve Stimulation
Protocol Percutaneous Tibial Nerve Stimulation (701106) Medical Benefit Effective Date: 10/01/15 Next Review Date: 07/18 Preauthorization No Review Dates: 09/09, 09/10, 07/11, 07/12, 07/13, 07/14, 07/15,
More informationMedical Coverage Policy Prostatic Urethral Lifts
Medical Coverage Policy Prostatic Urethral Lifts EFFECTIVE DATE:12 01 2018 POLICY LAST UPDATED: 10 03 2017 OVERVIEW Benign prostatic hyperplasia is a common condition in older men that can lead to increased
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Periureteral Bulking Agents as a Treatment of Vesicoureteral Reflux (VUR) Page 1 of 14 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Periureteral Bulking Agents
More informationSacral Nerve Neuromodulation/Stimulation
Protocol Sacral Nerve Neuromodulation/Stimulation (70169) Medical Benefit Effective Date: 01/01/16 Next Review Date: 09/18 Preauthorization No Review Dates: 01/08, 11/08, 09/09, 09/10, 09/11, 09/12, 09/13,
More informationClinical Policy: Posterior Tibial Nerve Stimulation for Voiding Dysfunction
Clinical Policy: Reference Number: CP.MP.133 Last Review Date: 08/18 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications Revision Log Description
More informationSome of the electrothermal intradiscal procedures are briefly described.
Medical Coverage Policy Minimally Invasive Intradiscal and Annular Procedures for Back Pain EFFECTIVE DATE: 10 01 2004 POLICY LAST UPDATED: 07 18 2017 OVERVIEW This policy addresses a variety of minimally
More informationCorporate Medical Policy Gastroesophageal Reflux Disease, Transendoscopic Therapies
Corporate Medical Policy Gastroesophageal Reflux Disease, Transendoscopic Therapies File Name: Origination: Last CAP Review: Next CAP Review: Last Review: gastroesophageal_reflux_disease_transendoscopic_therapies
More informationPelvic Floor Stimulation as a Treatment of Urinary and Fecal Incontinence
Pelvic Floor Stimulation as a Treatment of Urinary and Fecal Incontinence Policy Number: 1.01.17 Last Review: 2/2018 Origination: 2/2007 Next Review: 2/2019 Policy Blue Cross and Blue Shield of Kansas
More informationMedical Policy Title: Periureteral Bulking ARBenefits Approval: 10/26/201
Medical Policy Title: Periureteral Bulking ARBenefits Approval: 10/26/201 Agents as a Treatment of Vesicoureteral Reflux (VUR) Effective Date: 01/01/2012 Document: ARB0278 Revision Date: Code(s): 52327
More informationPolyacrylamide Hydrogel (Bulkamid ) in Female Patients of 80 or More Years with Urinary Incontinence
ORIGINAL ARTICLE Vol. 40 (1): 37-43 January - February, 2014 doi: 10.1590/S1677-5538.IBJU.2014.01.06 Polyacrylamide Hydrogel (Bulkamid ) in Female Patients of 80 or More Years with Urinary Incontinence
More informationPopulations Interventions Comparators Outcomes Individuals: With urinary incontinence
Pelvic Floor Stimulation as a Treatment of Urinary and Fecal (10117) Medical Benefit Effective Date: 07/01/14 Next Review Date: 05/18 Preauthorization No Review Dates: 01/08, 11/08, 09/09, 05/10, 05/11,
More informationClose. Number: Policy. Last Review 07/14/2016 Effective: 04/30/2002 Next Review: 07/13/2017. Review History
1 of 55 Close Number: 0611 Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB. Last Review 07/14/2016 Effective: 04/30/2002 Next Review: 07/13/2017 I. Aetna considers the following
More informationInitial Results of a New Bulking Agent for Fecal Incontinence: A Multicenter Study
ORIGINAL CONTRIBUTION Initial Results of a New Bulking Agent for Fecal Incontinence: A Multicenter Study Guillermo Rosato, M.D. 1 Pablo Piccinini, M.D. 2 Lucia Oliveira, M.D., Ph.D. 3 Angelita Habr-Gamma,
More informationClinical Policy: Posterior Tibial Nerve Stimulation for Voiding Dysfunction Reference Number: CP.MP.133
Clinical Policy: Reference Number: CP.MP.133 Effective Date: 10/16 Last Review Date: 10/16 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications
More informationEfficacy of dextranomer hyaluronic acid and polyacrylamide hydrogel in endoscopic treatment of vesicoureteral reflux: A comparative study
Original research Efficacy of dextranomer hyaluronic acid and polyacrylamide hydrogel in endoscopic treatment of vesicoureteral reflux: A comparative study Anne-Sophie Blais, MD; Fannie Morin, MD; Jonathan
More informationCorporate Medical Policy
Corporate Medical Policy Sacral Nerve Neuromodulation/Stimulation for Pelvic Floor Dysfunction File Name: Origination: Last CAP Review: Next CAP Review: Last Review: sacral_nerve_neuromodulation_stimulation_for_pelvic_floor_dysfunction
More informationDescription. Section: Medicine Effective Date: April 15, 2017 Subsection: Medicine Original Policy Date: June 7, Page: 1 of 6.
Page: 1 of 6 Last Review Status/Date: March 2017 Description Radiofrequency energy has been investigated as a minimally invasive treatment of fecal incontinence, in a procedure referred to as the Secca
More informationDescription. Section: Surgery Effective Date: April 15, Subsection: Surgery Original Policy Date: December 6, 2012 Subject:
Last Review Status/Date: March 2015 Page: 1 of 11 Description Vesicoureteral reflux (VUR) is the retrograde flow of urine from the bladder upward toward the kidney and is most commonly seen in children.
More informationPercutaneous Tibial Nerve Stimulation
Protocol Percutaneous Tibial Nerve Stimulation (701106) Benefit Effective Date: 10/01/18 Next Review Date: 07/19 Preauthorization No Review Dates: 09/09, 09/10, 07/11, 07/12, 07/13, 07/14, 07/15, 07/16,
More informationDOWNLOAD OR READ : URINARY FECAL INCONTINENCE CURRENT MANAGEMENT CONCEPTS URINARY AND FECAL INCONTINENCE PDF EBOOK EPUB MOBI
DOWNLOAD OR READ : URINARY FECAL INCONTINENCE CURRENT MANAGEMENT CONCEPTS URINARY AND FECAL INCONTINENCE PDF EBOOK EPUB MOBI Page 1 Page 2 urinary fecal incontinence current pdf Discusses urinary incontinence
More informationMEDICAL POLICY SUBJECT: SACRAL NERVE STIMULATION. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: SACRAL NERVE STIMULATION EFFECTIVE DATE: 11/19/99 PAGE: 1 OF: 9 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial
More informationThe number of Chiropractic visits allowed per year may vary according to the member s specific benefit.
Payment Policy Chiropractic Services EFFECTIVE DATE:07 21 2009 POLICY LAST UPDATED: 04 17 2018 OVERVIEW Chiropractic is a healthcare profession that focus on disorders of the musculoskeletal and nervous
More informationMedical Coverage Policy Functional Neuromuscular Electrical Stimulation EFFECTIVE DATE: 10/16/212 POLICY LAST UPDATED: 09/11/2014
Medical Coverage Policy Functional Neuromuscular Electrical Stimulation EFFECTIVE DATE: 10/16/212 POLICY LAST UPDATED: 09/11/2014 OVERVIEW Neuromuscular Electrical Stimulation, (NMES), involves the use
More informationAn open multicenter study of polyacrylamide hydrogel (Bulkamid ) for female stress and mixed urinary incontinence
Int Urogynecol J (2010) 21:1471 1477 DOI 10.1007/s00192-010-1214-1 ORIGINAL ARTICLE An open multicenter study of polyacrylamide hydrogel (Bulkamid ) for female stress and mixed urinary incontinence Gunnar
More informationPosterior Tibial Nerve Stimulation for Voiding Dysfunction
Posterior Tibial Nerve Stimulation for Voiding Dysfunction Corporate Medical Policy File name: Posterior Tibial Nerve Stimulation for Voiding Dysfunction File code: UM.NS.05 Origination: 8/2011 Last Review:
More informationPercutaneous Tibial Nerve Stimulation
7.01.106 Percutaneous Tibial Nerve Stimulation Section 7.0 Surgery Subsection Effective Date February 27, 2015 Original Policy Date February 27, 2015 Next Review Date February 2016 Description Percutaneous
More informationCorporate Medical Policy
Corporate Medical Policy Biofeedback as a Treatment of Pain File Name: Origination: Last CAP Review: Next CAP Review: Last Review: Biofeedback_as_a_treatment_of_pain 2/2017 5/2018 5/2019 5/2018 Description
More informationSubject: Temporary Prostatic Stent and Prostatic Urethral Lift
02-54000-21 Original Effective Date: 03/15/05 Reviewed: 09/27/18 Revised: 10/15/18 Subject: Temporary Prostatic Stent and Prostatic Urethral Lift THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION,
More informationClinical Policy: Biofeedback Reference Number: CP.MP.168
Clinical Policy: Reference Number: CP.MP.168 Effective Date: 07/17 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More information